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A key element to the prevention and management of the COVID-19 pandemic is the 
development of effective therapeutics.  Drug combination strategies of repurposed drugs offer 
a number of advantages to monotherapies including the potential to achieve greater efficacy, 
the potential to increase the therapeutic index of drugs and the potential to reduce the 
emergence of drug resistance.  Combination of agents with antiviral mechanisms of action with 
immune-modulatory or anti-inflammatory drug is also worthy of investigation. Here, we report 
on the in vitro synergistic interaction between two FDA approved drugs, remdesivir (RDV) 
and ivermectin (IVM) resulting in enhanced antiviral activity against SARS-CoV-2, the 
causative pathogen of COVID-19.  These findings warrant further investigations into the 
clinical potential of this combination, together with studies to define the underlying 
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Introduction 
As of the end of 2020, the WHO has reported more than 76 million confirmed cases of COVID-
19, including over 1.6 million deaths 1.  As part of an overarching strategy that includes the 
development of effective vaccines and rapid diagnostics, considerable efforts are underway to 
identify therapeutics to prevent and treat COVID-19.  Potential therapeutic strategies may 
include investigating the repurposing of existing drugs to the discovery of novel therapies.  
Thousands of clinical trials are currently underway, with therapeutic approaches involving 
direct-acting antivirals, for the prevention of virus replication, and host-directed therapies 
aimed at mitigating against the pathology of the disease 2, 3.   
 
Towards these efforts, strategies to identify effective combination therapies are emerging, with 
several laboratories reporting in vitro combination screens 4 and in vivo animal combinations 
studies 5.  A large number of clinical trials are also evaluating combination approaches 6.  There 
are several advantages of effective drug combinations, including: (i) achieving greater efficacy 
(reducing mortality and morbidity), (ii) prevention/minimisation of the emergence of drug 
resistance, and (iii) increasing the therapeutic index of drugs that show synergistic antiviral 
effects. Importantly, even in the absence of synergy an additive antiviral interaction for two 
drugs with separate mechanisms of action may profoundly reduce the speed at which drug 
resistance is transmitted.  An example of the benefits of a drug combination approach can be 
seen in HIV treatment, where antiretroviral combination drug treatment has resulted in 
dramatic improvements in both patient morbidity and mortality 7. Other clear examples also 
exist for other viruses, where HCV became the first chronic viral disease to become curable 
with drug combinations.  
 
Two repurposed drugs that have received notable attention for the treatment of COVID-19 
include remdesivir (RDV) and ivermectin (IVM).  RDV is a prodrug C-adenosine nucleoside 
analog that inhibits the viral RNA-dependent, RNA polymerase which has demonstrated in 
vitro inhibitory activity against SARS-CoV-1 and Middle East respiratory syndrome (MERS-
CoV)8, 9.  RDV was shown early in the pandemic to display in vitro antiviral efficacy against 
SARS-CoV-2 10 and has subsequently been investigated in several human clinical trials.  In a 
recently published double-blind, randomized, placebo-controlled trial, intravenous 
administration of RDV showed superiority relative to placebo in shortening the time to 
recovery in adults who were hospitalized with COVID-19 11.  RDV is currently the only FDA 
licenced drug approved for the treatment of COVID-19, but on 20th November 2020 the WHO 
issued a conditional recommendation against the use of RDV in hospitalised patients 
(irrespective of disease severity) because there is no evidence supporting an improvement in 
survival or other outcomes in these patients.  A combination of antivirals, and/or a combination 
between antivirals and anti-inflammatory/immunomodulatory agents may have more success. 
 
IVM is an FDA-approved anti-parasitic drug active against a wide range of parasites, including 
gastrointestinal roundworms, lungworms, mites, lice, hornflies and ticks12.  In addition, IVM 
is reported to exhibit broad spectrum anti-viral activity against a wide range of RNA and DNA 
viruses 13.  Recently, IVM was also shown to display anti-viral activity against SARS-CoV-2 
14, but approved doses are not expected to be high enough to achieve in vitro-defined target 
exposures systemically 15.  Several clinical trials are now evaluating the potential of IVM for 
both prophylaxis and treatment of COVID-19, but the low exposures make the anti-
inflammatory and/or immunomodulatory mechanisms of action more plausible than a direct 
antiviral activity of the monotherapy 16.  In nematodes and insects, IVM has been shown to 
target glutamate-gated Cl− channels (GUCl−, 13), whilst its antiviral properties may be the result 
of interaction with viral and/or host factors. For example, IVM displays anti-flavivirus activity 
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via inhibition of the viral NS3 helicase 17.  In addition, IVM has also been shown to inhibit 
classical nuclear transport of viral proteins (e.g. DENV NS5) via disruption of the importin α/β 
heterodimer 14. However, studies with SARS-CoV-2 in Syrian Golden Hamsters showed an 
impact upon disease pathology in the absence of any effect on viral titres 18. 
 
Here, using a classic combination testing approach to determine the Fractional Inhibitory 
Concentration Index (FICI), we report a synergistic interaction between RDV and IVM 
resulting in improved in vitro antiviral activity against SARS-CoV-2.  The data are discussed 
in the context of current therapeutic efforts against COVID-19. 
 
Methods 
SARS-CoV-2 Strain.  SARS-CoV-2/Human/Liverpool/REMRQ0001/2020 was isolated from 
a nasopharyngeal swab from a patient in Liverpool and passaged a further 4 times in Vero E6 
cells. The mapped RNA sequence has previously been submitted to Genbank, accession 
number MW041156. 
 
VERO E6 cell culture and plate preparation.  VERO E6 cells were maintained in complete 
EMEM (EMEM supplemented with 10% heat-inactivated FBS [Gibco; 10500-064] and 1% 
penicillin/streptomycin [Gibco; 15140-122]) at 37 °C with 5 % CO2. VERO E6 cells were not 
allowed to exceed 80 % confluence in culture and were not propagated beyond passage 15. 
Cells were harvested from flasks by removing the media, washing with PBS, and incubated 
them at 37 °C with 5 % CO2 for 10 min with trypsin-EDTA (Sigma-Aldrich; T4049). Cells 
were transferred to 50 mL centrifuge tubes in resting EMEM (EMEM supplemented with 10 
% heat-inactivated FBS) and enumerated. Cells were seeded in resting EMEM at 1 × 105 
cells/well in 96-well plates (Grenier Bio-one; 655090). Plates were then incubated for 20 h at 
37 °C with 5 % CO2 to allow the cells to reach 100 % confluence. The resting minimal medium 
was then removed, and the cells used for downstream applications. 
 
Measurement of drug efficacy against SARS-Cov-2 and assessment of the Fractional 
Inhibitory Concentration Index for RDV-IMC combinations.  In order to generate EC50s 
for RDV and IVM, VERO E6 cells were treated with either drug in minimal medium at 25.00 
μM, 8.33 μM, 2.78 μM, 0.93 μM, 0.31 μM, 0.10 μM and 0.03 μM (DMSO maintained at 
0.25%) or control media, as appropriate in 96-well plates. The plates were then incubated at 
37°C with 5% CO2 for 2 h to mimic prophylaxis treatment. Following this incubation, the 
minimal medium containing the experimental compounds and the control media was removed 
and wells were then treated with 50 μL minimal medium containing SARS-CoV-2 (MOI of 
0.05).  After addition of virus, 100 μL 2× semi-solid media and then 50 μL minimal medium 
containing experimental compounds and control media, as appropriate were added. The plates 
were allowed to incubate for 48 h, and then fixed by the addition of 4 % paraformaldehyde for 
1 h at room temperature. Following fixation, the media from each well was removed and cells 
stained with 0.25 % (w/v) crystal violet. Following (3 x) washing with dH2O2, cytopathic viral 
activity was determined by measuring absorbance of each well at 590 nm using a Varioskan 
LUX microplate reader (Thermo Fisher Scientific). 
Following the assessment of the inhibitory effect (EC50) of RDV and IVM monotherapy on the 
cytopathic viral activity of SARS-CoV-2, combination studies and analyses of the Fractional 
Inhibitory Concentration Index (FICI) were undertaken using the method of Berenbaum 19.  
Interpretation of FICI (FICI<=0.5 = synergy; FICI>4.0 = antagonism; FICI>0.5-4 = no 
interaction) follows guidance provided by the Journal of Antimicrobial Chemotherapy 20. All 
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monotherapy and combination drug sensitivity experiments were performed using three 
technical replicates and using at least two independent biological replicates. 
Results 
Initial experiments were conducted to confirm the anti-SARS-CoV-2 activity of IVM and RDV 
monotherapies.  Dose-effect relationship for the inhibition (%) of SARS-CoV-2 cytopathic 
activity for both drugs is shown in Fig. 1.  The measured EC50 for IVM was 2.3 ± 1.0 µM and 
EC50 for RDV was 1.9 ± 1.4 µM.  These values closely match those reported in recent studies 
for both drugs 10,14. 
 
Subsequent determination of the IVM-RDV combination interaction using isobologram 
analysis revealed a FICI<=0.5 indicating a synergistic interaction (Fig. 2). 
 
Discussion 
Here, we described the synergistic interaction between two FDA approved drugs resulting in 
enhanced in vitro antiviral activity against SARS-CoV-2, the causative pathogen of COVID-
19.  Although combination therapy offers a number of explicit advantages, genuine 
descriptions of synergy are relatively infrequent 21.  This observation appears to also be relevant 
to SARS-CoV-2 as there have been very few reports of validated synergistic interactions, 
despite thousands of combination experiments e.g. 4, 22. 
 
At this stage, the mechanism underpinning the synergistic interaction between RDV and IVM 
resulting in improved in vitro efficacy against SARS-CoV-2 is unclear.  Both drugs have 
previously been shown to inhibit SARS-CoV-2 replication 10, 14.  Given that RDV has a well-
defined mechanism of action and is known to inhibit the RNA-dependent, RNA polymerase 8, 
it will be of interest to investigate whether IVM provides synergy by also inhibiting an as yet 
defined alternative but complimentary function of RNA replication in SARS-CoV-2. 
 
At the doses currently being investigated for SARS-CoV-2, the known plasma 
pharmacokinetics suggest that concentrations sufficient to inhibit viral replication will not be 
achieved in plasma15.  However, modelling approaches indicate that inhibitory concentrations 
may be achieved in lung15, although this has been questioned by other authors23.  Nonetheless, 
a combination containing IVM may offer the opportunity to exploit the anti-inflammatory 
and/or immunomodulatory activity of this agent, while simultaneously augmenting the 
antiviral activity of viral RNA polymerase inhibitors like RDV. If this synergy is also evident 
with orally bioavailable polymerase inhibitors such as favipiravir or molnupiravir, the approach 
may be more widely exploitable for community deployment in earlier disease. However, given 
the low exposures of IVM, an additional drug with an achievable antiviral mechanism of action 
may also help stem emergence and transmission of resistance. 
 
Further investigation is now required to determine whether the observed synergistic interaction 
can be replicated in animal models of COVID-19 disease, and if these results are favourable, 
whether the finding can be translated to the clinic. It remains to be determined whether or not 
the synergistic RDV-IVM interaction will result in a favourable shift in the plasma Cmax/EC90 
ratio.  Nevertheless, the underpinning mechanisms for this synergy warrant further 
investigation so that this pharmacodynamic advantage can be exploited for future development 
of optimal drug combinations. 
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Figure 1. Dose-effect relationship for the inhibition (%) of SARS-CoV-2 cytopathic activity 
by (A) Ivermectin (IVM) and (B) Remdesivir (RDV). Non-linear regression was performed on 
data (mean ± S.D.) taken from a minimum of two independent biological replicates each 





Figure 2.  Isobologram showing interactions between Remdesivir and Ivermectin. 
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